MOUNTAIN VIEW, Calif., May 14 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services for optimizing clinical drug development, today announced that Kevin Dykstra, Ph.D., Vice President and Lead Scientist, Strategic Consulting Services, has been invited to speak to members of the pharmaceutical and biotechnology industries attending the 30th Annual Midwest Biopharmaceutical Statistics Workshop, to be held in Muncie, Indiana at Ball State University on May 21-23, 2007.
Dr. Dykstra will present a model-based case study that features development of a quantitative metric to assess the competing considerations affecting a treatment’s clinical utility. The title of Dr. Dykstra’s presentation is “Examining Clinical Utility: A New Formulation for an Old Drug.” Dr. Dykstra’s talk is part of dedicated conference session on modeling and simulation, which brings together pharmaceutical scientists from industry, government and academia. The session will include applied examples of model- based drug development in several therapeutic areas, and will describe research on how modeling and simulation has been used to predict expected clinical outcomes and support decision-making. The session will also provide a forum for scientific discussion and collaborative exchange on biostatistical topics in drug development. Additional information can be found at www.mbswonline.com.
“Model-based drug development continues to show value for improving the confidence of drug development decisions,” said Shawn O’Connor, president, CEO, and chairman of Pharsight. “A clinical utility index, or CUI, openly evaluates a product’s attributes and chance of success. Linking a CUI to predictive models of drug action and effect can support critical program decisions, such as whether reformulating an existing drug provides sufficient patient benefit to warrant further investment. Pharsight is pleased to participate at the Midwest Biopharmaceutical Statistics Workshop, and to exchange information and best practices with industry colleagues on the strategic use of modeling and simulation.”
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company’s goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight’s approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com .
Registered Trademarks and Trademarks
Pharsight is a registered trademark of Pharsight Corporation. All other brand and product names are trademarks or registered trademarks of their respective holders.
Pharsight Corporation
CONTACT: Investors, Jennifer Beugelmans, +1-646-201-5447, or DouglasSherk, +1-415-896-6820, or Media, Jennifer Saunders, +1-646-201-5431, allof EVC Group, for Pharsight Corporation
Web site: http://www.pharsight.com/
